Rolf Lewensohn

9.7k total citations · 1 hit paper
223 papers, 7.1k citations indexed

About

Rolf Lewensohn is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rolf Lewensohn has authored 223 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Molecular Biology, 80 papers in Oncology and 65 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rolf Lewensohn's work include Lung Cancer Treatments and Mutations (32 papers), DNA Repair Mechanisms (27 papers) and Cancer-related Molecular Pathways (18 papers). Rolf Lewensohn is often cited by papers focused on Lung Cancer Treatments and Mutations (32 papers), DNA Repair Mechanisms (27 papers) and Cancer-related Molecular Pathways (18 papers). Rolf Lewensohn collaborates with scholars based in Sweden, United States and Denmark. Rolf Lewensohn's co-authors include Kristina Viktorsson, Signe Friesland, Ingmar Lax, Boris Zhivotovsky, Janne Lehtiö, Luigi De Petris, Ulrik Ringborg, Jan Nyman, Florin Sirzén and Eva Munck‐Wikland and has published in prestigious journals such as Journal of Clinical Oncology, Genes & Development and Blood.

In The Last Decade

Rolf Lewensohn

223 papers receiving 6.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy

2009 653 citations Rolf Lewensohn et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rolf Lewensohn Sweden	42	3.1k	2.3k	2.0k	1.3k	1.2k	223	7.1k
Adrian C. Begg Netherlands	43	2.4k 0.8×	1.8k 0.8×	1.8k 0.9×	1.8k 1.4×	712 0.6×	128	6.5k
Anatoly Dritschilo United States	49	4.6k 1.5×	1.7k 0.8×	2.7k 1.4×	1.6k 1.2×	708 0.6×	280	8.3k
Peter B. Schiff United States	34	2.9k 0.9×	1.8k 0.8×	4.7k 2.4×	680 0.5×	639 0.5×	124	9.1k
Albert J. van der Kogel Netherlands	53	2.4k 0.8×	2.1k 0.9×	1.2k 0.6×	3.0k 2.4×	1.0k 0.9×	140	8.2k
Jan Alsner Denmark	45	2.8k 0.9×	1.5k 0.7×	2.0k 1.0×	2.6k 2.1×	471 0.4×	176	6.6k
Luka Milas United States	53	3.6k 1.1×	2.8k 1.2×	4.5k 2.3×	1.8k 1.5×	410 0.3×	201	9.9k
Dominic T. Moore United States	42	2.7k 0.9×	2.1k 0.9×	3.5k 1.8×	2.8k 2.2×	291 0.2×	128	8.0k
Takashi Nakano Japan	45	1.5k 0.5×	4.4k 1.9×	2.2k 1.1×	791 0.6×	1.4k 1.2×	456	8.8k
Rupert Schmidt‐Ullrich United States	51	2.8k 0.9×	2.5k 1.1×	2.5k 1.3×	2.1k 1.6×	1.9k 1.6×	186	9.0k
J. Denekamp United Kingdom	52	2.7k 0.9×	2.6k 1.1×	1.7k 0.9×	2.6k 2.0×	1.4k 1.1×	206	9.0k

Countries citing papers authored by Rolf Lewensohn

Since Specialization

Citations

This map shows the geographic impact of Rolf Lewensohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rolf Lewensohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rolf Lewensohn more than expected).

Fields of papers citing papers by Rolf Lewensohn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rolf Lewensohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rolf Lewensohn. The network helps show where Rolf Lewensohn may publish in the future.

Co-authorship network of co-authors of Rolf Lewensohn

This figure shows the co-authorship network connecting the top 25 collaborators of Rolf Lewensohn. A scholar is included among the top collaborators of Rolf Lewensohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rolf Lewensohn. Rolf Lewensohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tsakonas, Georgios, Per Hydbring, Kenbugul Jatta, et al.. (2024). Treatment of metastatic ALK-positive non-small cell lung cancer: real-world outcomes in a single center study. Translational Lung Cancer Research. 13(11). 2918–2933. 1 indexed citations

Ruysscher, Dirk De, Bart Reymen, Maarten Lambrecht, et al.. (2023). 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial. Radiotherapy and Oncology. 181. 109492–109492. 25 indexed citations

Gestin, Maxime, Petra Hååg, Rolf Lewensohn, et al.. (2023). Multi-marker profiling of extracellular vesicles using streaming current and sequential electrostatic labeling. Biosensors and Bioelectronics. 227. 115142–115142. 5 indexed citations

Franzén, Bo, Anca Dragomir, Gert Auer, et al.. (2023). Multiplex protein analysis and ensemble machine learning methods of fine needle aspirates from prostate cancer patients reveal potential diagnostic signatures associated with tumour grade. Cytopathology. 34(4). 286–294. 5 indexed citations

Ekman, Simon, Zsolt Cselényi, Andrea Varrone, et al.. (2023). Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study. Clinical and Translational Science. 16(6). 955–965. 7 indexed citations

Viktorsson, Kristina, Petra Hååg, Bo Franzén, et al.. (2022). Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome. Molecular Oncology. 16(20). 3620–3641. 6 indexed citations

Hååg, Petra, et al.. (2022). Cytotoxic Alkylynols of the Sponge Cribrochalina vasculum: Structure, Synthetic Analogs and SAR Studies. Marine Drugs. 20(4). 265–265. 3 indexed citations

Hååg, Petra, Magnus Olsson, Marita Lagergren Lindberg, et al.. (2022). Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia. Cell Death Discovery. 8(1). 284–284. 2 indexed citations

Hååg, Petra, Kristina Viktorsson, Anatol Krozer, et al.. (2021). Comparison and optimization of nanoscale extracellular vesicle imaging by scanning electron microscopy for accurate size-based profiling and morphological analysis. Nanoscale Advances. 3(11). 3053–3063. 13 indexed citations

10.

Franzén, Bo, Kristina Viktorsson, Vitali Grozman, et al.. (2021). Multiplex immune protein profiling of fine‐needle aspirates from patients with non‐small‐cell lung cancer reveals signatures associated with PD‐L1 expression and tumor stage. Molecular Oncology. 15(11). 2941–2957. 10 indexed citations

11.

Ekman, Simon, Andrea Varrone, Aurelija Jučaitė, et al.. (2019). P2.14-33 An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases. Journal of Thoracic Oncology. 14(10). S842–S842. 1 indexed citations

12.

Gréen, Henrik, Ilya Kupershmidt, Daniel Edsgärd, et al.. (2015). Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. Clinical Cancer Research. 22(2). 366–373. 20 indexed citations

13.

Viktorsson, Kristina, Petra Hååg, Katarina Färnegårdh, et al.. (2014). Marine Sponge Cribrochalina vasculum Compounds Activate Intrinsic Apoptotic Signaling and Inhibit Growth Factor Signaling Cascades in Non–Small Cell Lung Carcinoma. Molecular Cancer Therapeutics. 13(12). 2941–2954. 11 indexed citations

14.

Zong, Dali, et al.. (2014). Harnessing the lysosome-dependent antitumor activity of phenothiazines in human small cell lung cancer. Cell Death and Disease. 5(3). e1111–e1111. 36 indexed citations

15.

Viktorsson, Kristina, Lena Kanter, Amir Sherif, et al.. (2014). Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma. Urologic Oncology Seminars and Original Investigations. 32(8). 1215–1224. 9 indexed citations

16.

Chauhan, Dharminder, Arghya Ray, Kristina Viktorsson, et al.. (2013). In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells. Clinical Cancer Research. 19(11). 3019–3031. 79 indexed citations

17.

Ståhl, Sara, Vitaliy O. Kaminskyy, Alena Hyršlová Vaculová, et al.. (2013). Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412. Cell Death and Disease. 4(1). e454–e454. 21 indexed citations

18.

Aesöy, Reidun, et al.. (2008). An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells. Molecular Cancer Research. 6(10). 1630–1638. 84 indexed citations

19.

Petris, Luigi De, Lukas M. Orre, Lena Kanter, et al.. (2008). Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. Lung Cancer. 63(3). 410–417. 51 indexed citations

20.

Fagerberg, Jan, Dag Stockeld, & Rolf Lewensohn. (1994). Combined Treatment Modalities in Esophageal Cancer: Should chemotherapy be included?. Acta Oncologica. 33(4). 439–450. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact